Stock ALM ALMIRALL, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News Almirall, S.A.

Equities

ALM

ES0157097017

Market Closed - BME
Other stock markets
 11:35:01 2024-04-23 am EDT 		After market 03:59:53 pm
8.36 EUR +1.46% Intraday chart for Almirall, S.A. 8.373 +0.16%
Mar. 13 Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment MT
Feb. 19 Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... Our Logo

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BU
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment
MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...
Our Logo
Almirall: share price surges after agreement with Novo Nordisk
CF
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk
MT
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
BU
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk
CI
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
BU
Almirall, S.A. Provides Earnings Guidance for the Year 2024
CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Almirall, S.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
BU
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
CI
Almirall: messenger RNA alliance with Belgium's etherna
CF
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies
MT
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
BU
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology
CI
Certain Shares of Almirall, S.A. are subject to a Lock-Up Agreement Ending on 10-DEC-2023.
CI
Almirall: share price rises, EU green light for eczema treatment
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALM Stock
  4. News Almirall, S.A.